Igea J M, Cuevas M, Lázaro M, Quirce S, Cuesta J
Clínica Alergoasma, Salamanca, Spain.
Allergol Immunopathol (Madr). 1994 Mar-Apr;22(2):55-9.
The oral and sublingual immunotherapy is still a controversial therapeutic procedure. One of the problems is knowing how much allergenic activity could the extracts loss due to the digestive process into the mouth and stomach. Using a grass-pollen oral and sublingual immunotherapy extract, we studied its degradation until reaching the small intestine. For this purpose we employed an in vitro model using the RAST-inhibition assay. We observed a 3.8 fold loss of allergenic activity after a 30 sec-incubation with saliva; a subsequent 5 min-incubation with gastric fluid got a final loss of allergenic activity of 10.3 fold. The incubation times were those expected occurring during the ingestion of the extract. It was surprising that after the enzymatic and acid actions of the gastric fluid, an important degree of allergenic activity still remained in the extract. This issue should be taken into account when considering the dose to be administered in oral and sublingual immunotherapy.
口服和舌下免疫疗法仍然是一种存在争议的治疗方法。问题之一在于，不清楚提取物在口腔和胃的消化过程中会损失多少变应原活性。我们使用一种草花粉口服和舌下免疫疗法提取物，研究了其在到达小肠之前的降解情况。为此，我们采用了一种使用RAST抑制试验的体外模型。我们观察到，提取物与唾液孵育30秒后，变应原活性损失了3.8倍；随后与胃液孵育5分钟后，变应原活性最终损失了10.3倍。孵育时间是提取物摄入过程中预期会出现的时间。令人惊讶的是，在胃液的酶解和酸作用之后，提取物中仍保留了相当程度的变应原活性。在考虑口服和舌下免疫疗法的给药剂量时，应考虑到这一问题。
